Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Use Of Immunomicelles To Treat Ovarian Cancer

David R. Khan, Shelby M. Phelps, J. Yarbrough, James D Woodyard, A. E. Muniz
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The use of nannocarriers in general for the delivery of cytotoxic agents to solid tumors is ideal as they have been shown to improve the overall pharmacological properties of otherwise low-molecular weight “free drugs”, or unencapsulated cytotoxic agents by altering drug pharmacokinetics and biodistribution/bioavailability [1].
This paper references
10.1038/sj.onc.1203551
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
T. Hirano (2000)
10.1007/s10495-016-1339-x
Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells
C. Cárdenas (2016)
10.1002/cbin.10131
Overexpression of CD147 in ovarian cancer is initiated by the hypoxic microenvironment
H. Yang (2013)
GRP78 enabled micellebased glioma targeted drug delivery
D Ran (2017)
10.1038/nrc2761
Mucins in cancer: function, prognosis and therapy
D. Kufe (2009)
10.18632/oncotarget.7076
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
M. C. Palanca-Wessels (2016)
10.1016/j.ejpb.2014.07.001
The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.
C. Sarisozen (2014)
10.1016/j.jconrel.2012.09.003
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
F. Perche (2012)
Micelle Delivery System Loaded with a Pharmaceutical Agent. US
VP Torchilin (2006)
10.1371/journal.pone.0120129
Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly
Zhuoyang Fan (2015)
10.1007/s11095-016-1978-1
Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model
Bhushan S. Pattni (2016)
10.1016/j.carbpol.2016.08.021
Hyaluronic acid conjugated micelles possessing CD44 targeting potential for gene delivery.
W. J. Lin (2017)
10.1634/theoncologist.2019-0070
A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
B. Keam (2019)
10.1016/j.jconrel.2016.10.014
Precision targeted therapy of ovarian cancer.
Justin Sapiezynski (2016)
10.1016/j.ijpharm.2017.08.095
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG.
Bhushan S. Pattni (2017)
10.1016/j.ijrobp.2013.02.009
Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.
M. Werner (2013)
10.1016/j.biomaterials.2014.11.008
Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters.
M. Muthu (2015)
Transferrintargeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells
AH Abouzeid (2014)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1016/j.ijpharm.2008.01.041
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
T. Elbayoumi (2008)
10.1016/j.biopha.2017.09.006
Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil®.
Maximiliano Cagel (2017)
10.1155/2015/413076
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Nirmala Chandralega Kampan (2015)
10.1002/CHIN.201323239
Design, Functionalization Strategies and Biomedical Applications of Targeted Biodegradable/Biocompatible Polymer‐Based Nanocarriers for Drug Delivery
J. Nicolas (2013)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
10.2147/IJWH.S7012
Clinical trials and progress with paclitaxel in ovarian cancer
S. Kumar (2010)
10.2174/1877912311303010004
Recent Patents on Common Modifications Made to Traditional Micellar- Based Chemotherapeutics Designed to Improve Drug Delivery
D. R. Khan (2013)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
Prognostic, predictive and therapeutic Copyright
A Serrano Olvera (2006)
10.3109/09687688.2010.521200
Receptor-targeted nanocarriers for therapeutic delivery to cancer
B. Yu (2010)
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. oncologist
B Keam (2019)
10.1016/J.CTRV.2006.01.001
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
A. Serrano-Olvera (2006)
10.1038/modpathol.2014.114
Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression
J. Stewart (2015)
Micelle Delivery System Loaded with a Pharmaceutical Agent
V P Torchilin (2006)
10.1038/bjc.1993.517
Ovarian Cancer
I. Judson (1993)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
10.1186/1476-4598-13-129
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
M. Felder (2014)
10.3390/ijms19103030
Chemotherapeutic Efficacy of Implantable Antineoplastic-Treatment Protocols in an Optimal Mouse Model for Human Ovarian Carcinoma Cell Targeting
J. Pantshwa (2018)
10.1021/mp300633f
Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma.
R. Sawant (2014)
10.1158/1535-7163.MCT-06-0355
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
W. Depinto (2006)
10.21873/ANTICANRES.12353
Chemotherapeutic Effect of CD147 Antibody-labeled Micelles Encapsulating Doxorubicin Conjugate Targeting CD147-Expressing Carcinoma Cells.
T. Asakura (2018)
10.1016/j.bbagen.2011.07.016
The transferrin receptor and the targeted delivery of therapeutic agents against cancer.
T. R. Daniels (2012)
Recent Advancements Involving Immunoliposomes to Target Breast Cancer
Khan (2018)
10.1039/c6sc02403c
Antibody fragments as nanoparticle targeting ligands: a step in the right direction
Daniel A Richards (2017)



Semantic Scholar Logo Some data provided by SemanticScholar